Saving money on the PBS: ranibizumab or bevacizumab for neovascular macular degeneration?

Ken J. Harvey; Richard O. Day; William G. Campbell; Wendy Lipworth

Saving money on the PBS: ranibizumab or bevacizumab for neovascular macular degeneration?

Ken J. Harvey, Richard O. Day, William G. Campbell, Wendy Lipworth

Research output: Contribution to journal › Editorial

9 Citations (Scopus)

Abstract

The cost differential between these two drugs is no longer defensible.

Original language	English
Pages (from-to)	567-568
Number of pages	2
Journal	The Medical Journal of Australia
Volume	194
Issue number	11
Publication status	Published - 6 Jun 2011
Externally published	Yes

Keywords

Angiogenesis Inhibitors
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Australia
Bevacizumab
Health Policy
Humans
Macular Degeneration
National Health Programs
Off-Label Use
Randomized Controlled Trials as Topic
Ranibizumab

Access to Document

https://www.mja.com.au/journal/2011/194/11/saving-money-pbs-ranibizumab-or-bevacizumab-neovascular-macular-degeneration

Cite this

@article{cb14cc1d8bde491cb373f96d0254600e,

title = "Saving money on the PBS: ranibizumab or bevacizumab for neovascular macular degeneration?",

abstract = "The cost differential between these two drugs is no longer defensible.",

keywords = "Angiogenesis Inhibitors, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Australia, Bevacizumab, Health Policy, Humans, Macular Degeneration, National Health Programs, Off-Label Use, Randomized Controlled Trials as Topic, Ranibizumab",

author = "Harvey, \{Ken J.\} and Day, \{Richard O.\} and Campbell, \{William G.\} and Wendy Lipworth",

year = "2011",

month = jun,

day = "6",

language = "English",

volume = "194",

pages = "567--568",

journal = "The Medical Journal of Australia",

issn = "0025-729X",

publisher = "Wiley-Blackwell, Wiley",

number = "11",

}

TY - JOUR

T1 - Saving money on the PBS

T2 - ranibizumab or bevacizumab for neovascular macular degeneration?

AU - Harvey, Ken J.

AU - Day, Richard O.

AU - Campbell, William G.

AU - Lipworth, Wendy

PY - 2011/6/6

Y1 - 2011/6/6

N2 - The cost differential between these two drugs is no longer defensible.

AB - The cost differential between these two drugs is no longer defensible.

KW - Angiogenesis Inhibitors

KW - Antibodies, Monoclonal

KW - Antibodies, Monoclonal, Humanized

KW - Australia

KW - Bevacizumab

KW - Health Policy

KW - Humans

KW - Macular Degeneration

KW - National Health Programs

KW - Off-Label Use

KW - Randomized Controlled Trials as Topic

KW - Ranibizumab

UR - https://www.scopus.com/pages/publications/79958830007

M3 - Editorial

C2 - 21644867

SN - 0025-729X

VL - 194

SP - 567

EP - 568

JO - The Medical Journal of Australia

JF - The Medical Journal of Australia

IS - 11

ER -

Saving money on the PBS: ranibizumab or bevacizumab for neovascular macular degeneration?

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this